AI Terminal
INTELLIGENT ULTRASOUND GROUP PLC
Regulatory Filings • Jul 20, 2022
7714_rns_2022-07-20_908045a8-1553-43f3-aaa2-c346ce110585.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0250T
Intelligent Ultrasound Group PLC
20 July 2022
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Group" or the "Company")
AI technology incorporated into new GE Healthcare Voluson Expert 22 ultrasound system
Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces that GE Healthcare has incorporated the Company's ScanNav real-time AI technology into its new Voluson Expert 22 ultrasound machine.
The Voluson Expert 22 features SonoLyst, the world's first fully integrated AI tool that recognises the 21 views recommended by the International Society of Ultrasound in Obstetrics and Gynaecology mid-trimester practice guidelines for fetal imaging and incorporates Intelligent Ultrasound's ScanNav Assist AI technology.
This is the second machine in the Voluson portfolio to incorporate the ScanNav AI software as an option add-on.
Nicholas Sleep, CTO of Intelligent Ultrasound, said: "We are delighted to see our software incorporated into the Voluson Expert 22, one of the best obstetrics ultrasound machines in the women's healthcare market. It's a great example of how GE Healthcare leads the world in medical imaging.
"We look forward to continuing to work with the GE Healthcare team and remain very excited about our novel 'classroom-to-clinic' approach that is endeavouring to make clinical diagnostic ultrasound easier to learn and simpler to use."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
For further information, please contact:
| Intelligent Ultrasound Group plc | www. intelligentultrasound.com | |||||||||
| Stuart Gall, CEO | Tel: +44 (0)29 2075 6534 | |||||||||
| Helen Jones, CFO | ||||||||||
| Cenkos Securities - Nominated Advisor and Broker | ||||||||||
| Giles Balleny/Max Gould (Corporate Finance) | Tel: +44 (0)20 7397 8900 | |||||||||
| Michael Johnson/Julian Morse (Sales) | ||||||||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |||||||||
| Anna Dunphy/Paul McManus | Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893 | |||||||||
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:
Simulation
Real-time hi-fidelity ultrasound education and training through simulation. Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,400 simulators have been sold to c. 700 medical institutions around the world.
Clinical AI software
Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE Healthcare's SonoLyst software that is incorporated in their Voluson Expert 22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB.
NOTE: ScanNav Anatomy PNB is CE approved, but not yet available for sale in the US or any other territory requiring government approval for this type of product.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCRLMATMTBBBMT